Neuland Labs Q2 FY26 Total Income at ₹516.1 crore; EBITDA up 138.8% YoY to ₹156.9 crore
Neuland Labs reported strong Q2 FY26 results with total income of ₹516.1 crore and EBITDA of ₹156.9 crore, driven by CMS projects. Management expects continued momentum and growth.
The announcement details impressive financial performance for Q2 FY26, including significant revenue and profit growth, which is likely to positively influence investor confidence and the company's stock valuation.
The company reported substantial year-on-year growth across all key financial metrics, including total income, EBITDA, PBT, and PAT, with EBITDA increasing by 138.80% and PAT by 201.60%. Management commentary indicates strong performance driven by CMS projects and anticipates continued momentum and growth opportunities.
Neuland Laboratories Limited announced its financial results for the quarter and half year ended September 30, 2025: * Q2 FY26 Financial Highlights (YoY comparison): * Total Income: ₹516.1 crore, a 63.70% increase from ₹315.2 crore in Q2 FY25. * EBITDA: ₹156.9 crore, a significant 138.80% increase from ₹65.7 crore in Q2 FY25. * EBITDA Margin: Improved to 30.40% from 20.80% in Q2 FY25 (a 960 bps increase). * Profit Before Tax (PBT): ₹129.0 crore, up 166.00% from ₹48.5 crore in Q2 FY25. * Profit After Tax (PAT): ₹96.5 crore, up 201.60% from ₹32.0 crore in Q2 FY25. * Management Commentary: * Mr. Sucheth Davuluri, Vice-Chairman and CEO, stated that record high revenue, driven by CMS commercial projects, led to operating leverage reflected in EBITDA margins, and he expects this momentum to continue. * Mr. Saharsh Davuluri, Vice Chairman and Managing Director, noted increasing customer interest and engagement, leading to new business and greater share from existing customers, with investments progressing as planned. * Earnings Call: The company will conduct a one-hour Earnings call at 17:30 hrs. IST on Friday, November 7, 2025.
What to do with a filing like this
Neuland Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Neuland Laboratories Limited. Read the original for the full detail.